The purpose of our research was to observe the intervention of SGLT2i in type 2 diabetic patients with different levels of albuminuria for 12 weeks and to investigate the effect of SGLT2i on nephrin and TGF-β1 in urine, glucose and lipid metabolism, and low-grade inflammation in type 2 diabetes patients. Here, TGFB1 is linked to type 2 diabetes mellitus.